• Abstract and Figures
• Public Full-text

2007 ANNUAL REPORT IN SEARCH OF LASTING SOLUTIONS TO HIV/AIDS THE FOUNDATION FOR AIDS RESEARCH amfAR, THE FOUNDatION F O R A ID S R E S E ar C H , I S DEDICatED TO ENDING THE GLOBAL AIDS EPIDEMIC T H R O U G H I N N O V at I V E RESEARCH. Cover photos (from top): TREAT Asia Community Programs Manager Jennifer I-Ching Ho holds an HIV-positive child (photo: Karl Grobl); Dr. Nolwenn Jouvenet, Aaron Diamond AIDS Research Center (photo: Dr. Rowena Johnston); Shan Grant, Miguel Rivera, and Robert Green (photo: Winnie McCroy). FROM THE CHAIRMAN 02 A Global Force Against a Global Epidemic FROM THE CHIEF EXECUTIVE OFFICER 03 Good Research Drives Good Policy PEOPLE LIVING WITH HIV/AIDS 04 MAJOR ACCOMPLISHMENTS 06 RESEARCH 08 GLOBAL INITIATIVES 15 PUBLIC POLICY 22 EDUCATION AND INFORMATION 26 GIVING 30 Individual Giving Institutional Giving In-Kind Contributions Planned Giving Volunteer Support Workplace Giving FINANCIAL SUMMARY 44 From the Treasurer and the Chair of the Finance and Budget Committee Statement of Activities and Changes in Net Assets Statement of Financial Position LEADERSHIP AND ADVISORY COMMITTEES 46 ACKNOWLEDGMENTS FROM THE CHAIRMAN A Global FORCE AGAINST A Global EPIDEMIC Of the 33 million people living with HIV/AIDS, more than 90 percent are in the develop- ing world. For most of its 23 years at the leading edge of the fight against AIDS, amfAR has brought AIDS research, prevention, and education to countries hard hit by the epidemic. A global health threat demands nothing less than a global response. A couple of years ago, we changed our name from the American Foundation for AIDS Research to The Foundation for AIDS Research to reflect the increasingly international scope of both the epidemic and amfAR’s work. The TREAT Asia Network that amfAR formed in 2001 is now a highly regarded model of regional collaboration on HIV/AIDS research, education, and training across Asia and amfAR Annual Report 2007 amfAR the Pacific. In 2007 we launched an important new international venture: the MSM Initiative. The first round of community awards that form the core of this initiative will support front-line organizations working to combat the rapid and deadly spread of HIV among men who have sex with men (MSM) in Africa, the Caribbean, and Southeast Asia. In 2008, additional awards will be made for innovative programs in Latin America and Asia and the Pacific. Here in the U.S., some of our own cities have rates of infection that rival parts of the developing world. In Washington, D.C., one in 20 residents is HIV positive. So we continue to fight for evidence-based policies that are essential to reducing infection rates 02 and for adequate levels of government funding for HIV/AIDS research, treatment, and From the Chairman From prevention. The international growth of amfAR’s programs has been matched by a correspond- ing expansion in the fundraising arena. For many years, our successful Cinema Against AIDS series has raised funds and brought AIDS awareness to a global audience during the Cannes International Film Festival. In 2007 we were invited to bring the event to the Rome and Dubai film festivals. These new venues enable us to teach new audiences about the vital importance of AIDS research and to combat HIV-related stigma. Our fundraising efforts will be greatly assisted by the passion and dedication of Sharon Stone, who has taken on the role of global fundraising chairman. On the staff side, we are pleased that Kevin Frost, who ably served for many years as vice president for global initiatives, has accepted the position of chief executive officer. Kevin’s experi- ence, energy, and vision will help guide and drive amfAR as we expand our international initiatives while maintaining our fundamental commitment to AIDS research. As we embrace the challenges that confront us, we recognize that our work and accomplishments would not be possible without the continued support of generous individuals and organizations. Your ongoing commitment inspires us and enables us to quicken the pace of our efforts to end this deadly epidemic. Kenneth Cole Chairman of the Board FROM THE CHIEF EXECUTIVE OFFICER GOOD RESEARCH DRIVES GOOD POLICY I like to think that amfAR has the mind of a scientist and the soul of an activist. For 23 years, we have pushed at the frontiers of AIDS research, investing in unexplored areas that have yielded new treatments, improved prevention methods, and vital clues to HIV eradication. And we have pushed for AIDS-related policies rooted in science, compas- sion, and common sense. Both advocacy and research require patience and persistence, and can take years to bear fruit. Studies that amfAR funded in 1995, for example, pointed the way to the development and approval in 2007 of the first medication in a brand new class of AIDS drugs. These so-called CCR5 blockers bring an important new option—and new hope— to patients developing resistance to currently available treatments. While past amfAR grants and fellowships continue to influence the discoveries of today, we launched a new initiative in 2007 that will help shore up the future of AIDS research. Young scientists are often those with the most ingenious ideas, but increas- ingly fierce competition for funds threatens to drive them away from research on AIDS. Our Mathilde Krim Fellowships in Basic Biomedical Research provide a critical source of amfAR Annual Report 2007 amfAR funds that will help nurture these AIDS research leaders of tomorrow. While substantial resources are quite rightly being invested in the delivery of treat- 03 ment to those who need it, there is a growing consensus that insufficient attention is being paid to research. That consensus was enshrined in the Sydney Declaration of 2007, which recommends that 10 percent of all HIV/AIDS funding be devoted to research. amfAR was among almost 2,000 signatories of the Declaration, which stressed that the necessary research should extend well beyond the laboratory. Basic science is essential, of course, but above all, research is about people, communities, and human behavior. As the Sydney Declaration states, “good research drives good policy.” We couldn’t the Chief Executive Officer From agree more, since it is good policy that delivers the benefits of research to people. As scientists and activists, we shall continue to support the best AIDS research and the smartest AIDS policies until we bring this deadly epidemic to an end. Kevin Robert Frost Chief Executive Officer PEOPLE LIVING WITH HIV/AIDS, 2007 amfAR Annual Report 2007 amfAR North America 1.3 million (480,000–1.9 million) 04 Caribbean People Living With HIV/AIDS Living People 230,000 (210,000–270,000) World at a Glance • 33.2 million people were living with HIV/AIDS in 2007. Latin America • 2.1 million of them were 1.6 million under the age of 15. (1.4–1.9 million) • 2.5 million people were estimated to be infected with HIV in 2007. • 420,000 were under the age of 15. • 6,800 people contract HIV every day—283 every hour. • 2.1 million people died from AIDS in 2007. • 290,000 of them were under the age of 15. Source:Source: UNAIDSUNAIDS/World Health Organization Global Total: 33.2 million (30.6–36.1 million) Eastern Europe & Central Asia Western & 1.6 million Central Europe (1.2–2.1 million) 760,000 (600,000–1.1 million) East Asia 800,000 Annual Report 2007 amfAR (620,000–960,000) South & 05 Southeast Asia North Africa & 4 million Middle East (3.3–5.1 million) 380,000 (270,000–500,000) People Living With HIV/AIDS Living People Sub-Saharan Africa 22.5 million (20.9–24.3 million) Oceania 75,000 (53,000–120,000) The numbers indicated in parentheses define the boundaries within which the actual numbers lie, based on the best available information. MAJOR ACCOMPLISHMENTS, 2007 Securing the Future of AIDS Research Advocacy Efforts Pay Off Funding sources for promising young scientists have become amfAR has been a leading advocate of the increased federal increasingly difficult to secure, yet these same young research- funding for AIDS research that is necessary to continue U.S. ers are often those with the most innovative ideas. To support leadership in cutting-edge discoveries related to the preven- these future leaders of AIDS research and to advance their tion, care, and treatment of HIV/AIDS. The Foundation’s efforts promising studies, in 2007 amfAR launched the Mathilde Krim contributed to a $619.5 million increase in the FY 2007 budget Fellowships in Basic Biomedical Research. Named for amfAR’s of the National Institutes of Health and an additional $330 founding chairman, the million increase in FY 2008. amfAR Annual Report 2007 amfAR Krim Fellowships moved from concept to funding in Syringe Exchange Funding Ban Overturned less than a year. In Washington, D.C., where one in 20 residents is living with HIV, the federal government long banned the city from using New HIV/AIDS local taxpayer dollars to fund syringe exchange programs— Drug Class a proven approach to HIV prevention. Since the ban was Gains Approval imposed, amfAR has provided grants to support syringe In August, the Food and exchange in the District and has been vocal and persistent in Drug Administration its opposition to the ban. In 2007, both the House and Senate 06 approved maraviroc, the finally removed the restrictive legislative language, an advocacy Major Accomplishments Major first in a new class of anti- triumph that was a decade in the making. HIV drugs called CCR5- blockers. amfAR played Stemming the Tide of AIDS Among Men a major role in spurring Who Have Sex with Men the early development of maraviroc through initial research Recent studies show surging rates of HIV infection among men by amfAR grantee Dr.

Load more

  52

Copy Link